Spots Global Cancer Trial Database for inhl
Every month we try and update this database with for inhl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732913 | Indolent Non-Ho... | Placebo Rituximab Idelalisib | 18 Years - | Gilead Sciences | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
